Denali and Biogen Discontinue Parkinson's Drug BIIB122 After Phase 2b Trial Failure
summarizeSummary
Denali Therapeutics and Biogen are discontinuing their Parkinson's disease drug BIIB122 after its Phase 2b trial failed to meet efficacy endpoints, marking a major pipeline setback.
check_boxKey Events
-
Phase 2b LUMA Study Failed
The BIIB122 (DNL151) study in early-stage Parkinson's disease did not meet its primary or secondary endpoints for slowing disease progression.
-
Program Discontinuation
Biogen and Denali will discontinue further development of BIIB122 for idiopathic Parkinson's disease based on the trial results.
-
LRRK2 Variant Study Continues
Denali will independently continue the Phase 2a BEACON study of BIIB122 in carriers of a pathogenic LRRK2 variant, with data expected in H1 2027.
-
Biomarker Engagement Observed
Exploratory biomarker endpoints showed over 90% kinase inhibition of peripheral LRRK2 and a reduction in phosphorylated Rab10, indicating the drug engaged its target despite clinical failure.
auto_awesomeAnalysis
The Phase 2b LUMA study for BIIB122 in early-stage Parkinson's disease failed to meet its primary and secondary endpoints, leading Denali and Biogen to discontinue its development for idiopathic Parkinson's. This represents a significant setback for Denali's pipeline in a major neurodegenerative disease, despite the drug showing target engagement. The company will continue a separate Phase 2a study for a specific genetic variant.
At the time of this filing, DNLI was trading at $17.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $12.58 to $23.77. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.